India is preparing for a major shift in its healthcare landscape as cheaper versions of popular weight-loss medicines are expected to enter the market following the expiration of the semaglutide patent. The molecule behind blockbuster treatments such as Wegovy and Ozempic is now open to generic production in India, potentially reducing prices sharply and expanding access to millions of patients. According to BBC reporting, analysts believe this could mark a turning point not only for India’s obesity treatment sector but also for global access to modern weight-loss therapies.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which help regulate appetite and blood sugar levels. Originally developed to manage diabetes, the drug later gained global attention for its effectiveness in supporting weight reduction. With patent protection ending in India, domestic pharmaceutical companies are expected to introduce dozens of branded generic versions within months. Investment bank Jefferies described the moment as potentially transformative, suggesting the market for semaglutide based treatments in India alone could eventually reach one billion dollars.
India’s strong generics manufacturing ecosystem positions the country to move quickly. Major pharmaceutical firms including Cipla, Sun Pharma, Dr Reddy’s Laboratories, Biocon, Natco, Zydus and Mankind Pharma are preparing their own versions of the drug. Current monthly treatment costs range between roughly 8,800 and 16,000 rupees for branded injections, but competition could push prices down to about 3,000 to 5,000 rupees per month, making therapy far more affordable for a much wider population.
Demand for weight-loss medicines has already surged in recent years as lifestyle related diseases continue to rise. India currently has more than 77 million people living with type 2 diabetes and a rapidly growing population of overweight adults. Doctors are increasingly using GLP-1 medicines across multiple specialties including cardiology, orthopaedics and respiratory care to support patients before procedures and manage associated health conditions such as sleep apnoea and joint stress.
However, medical experts are urging caution as access expands. Physicians warn that misuse, unrealistic expectations and inadequate supervision could create new risks. Side effects such as nausea and digestive discomfort remain common, while rapid weight loss without proper nutrition and exercise may result in muscle loss. According to BBC reporting, regulators in India have also advised pharmaceutical companies not to promote prescription weight-loss medicines directly to consumers, emphasizing that these treatments should only be used under professional medical guidance.
India’s reputation as the pharmacy of the developing world could also play a major role globally. The country already supplies about 20 percent of the world’s generic medicines and exports pharmaceuticals to more than 200 countries. Experts believe lower cost semaglutide produced in India could eventually reach international markets, particularly as obesity rates continue rising worldwide. If managed carefully with strong quality control and oversight, India’s generics expansion could reshape access to weight-loss treatment across both emerging and developed economies.
